NYSE:ABT - Abbott Laboratories Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $121.56
  • Forecasted Upside: 10.17 %
  • Number of Analysts: 18
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 15 Buy Ratings
  • 0 Strong Buy Ratings
$110.33
▼ -1.3 (-1.16%)
1 month | 3 months | 12 months
Get New Abbott Laboratories Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABT

Average Price Target: $121.56
▲ +10.17% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is $121.56, with a high forecast of $140.00 and a low forecast of $94.00. The average price target represents a 10.17% upside from the last price of $110.33.

Buy

The current consensus among 18 polled investment analysts is to buy stock in Abbott Laboratories. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/26/2019
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 1 sell ratings
3/25/2020
  • 0 strong buy ratings
  • 15 buy ratings
  • 3 hold ratings
  • 1 sell ratings
6/23/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 3 hold ratings
  • 1 sell ratings
9/21/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 3 hold ratings
  • 1 sell ratings
12/20/2020
  • 0 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 1 sell ratings
5/19/2021
  • 0 strong buy ratings
  • 15 buy ratings
  • 2 hold ratings
  • 1 sell ratings
6/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 15 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/2/2021BTIG ResearchLower Price TargetBuy$140.00 ➝ $120.00Medium
6/2/2021Credit Suisse GroupLower Price TargetOutperform$133.00 ➝ $120.00Medium
6/2/2021BarclaysLower Price TargetOverweight$150.00 ➝ $125.00Medium
6/2/2021Wells Fargo & CompanyLower Price TargetOverweight$137.00 ➝ $125.00Medium
6/2/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price TargetBuy$138.00 ➝ $125.00Medium
6/2/2021Raymond JamesLower Price TargetOutperform$130.00 ➝ $116.00Medium
6/2/2021Morgan StanleyLower Price TargetOverweight$140.00 ➝ $126.00Medium
6/2/2021CitigroupReiterated RatingBuy$138.00 ➝ $125.00Medium
5/24/2021BarclaysInitiated CoverageOverweight$150.00Medium
4/21/2021Morgan StanleyBoost Price TargetOverweight$136.00 ➝ $140.00Medium
4/20/2021William BlairReiterated RatingOutperformLow
4/15/2021Atlantic SecuritiesInitiated CoverageNeutral$122.00High
3/11/2021Raymond JamesBoost Price TargetOutperform$126.00 ➝ $130.00Low
1/28/2021Wells Fargo & CompanyBoost Price Target$128.00 ➝ $137.00Medium
1/28/2021CowenBoost Price TargetOutperform$113.00 ➝ $140.00Medium
1/28/2021Credit Suisse GroupBoost Price TargetOutperform$118.00 ➝ $130.00High
1/28/2021Morgan StanleyBoost Price TargetOverweight$126.00 ➝ $136.00High
1/28/2021SVB LeerinkBoost Price TargetMarket Perform$115.00 ➝ $128.00High
1/28/2021Raymond JamesBoost Price TargetOutperform$114.00 ➝ $126.00High
1/28/2021BTIG ResearchUpgradeNeutral ➝ Buy$140.00High
12/15/2020Morgan StanleyBoost Price TargetOverweight$121.00 ➝ $126.00Low
11/19/2020Morgan StanleyBoost Price TargetOverweight$117.00 ➝ $121.00Low
10/22/2020Jefferies Financial GroupBoost Price TargetBuy$113.00 ➝ $123.00High
10/22/2020Credit Suisse GroupLower Price TargetOutperform$136.00 ➝ $118.00High
10/22/2020Raymond JamesBoost Price TargetMarket Perform ➝ Outperform$102.00 ➝ $114.00High
10/22/2020Morgan StanleyBoost Price TargetOverweight$112.00 ➝ $117.00High
10/22/2020SVB LeerinkBoost Price TargetPositive ➝ Market Perform$110.00 ➝ $115.00High
10/9/2020JPMorgan Chase & Co.Boost Price TargetOverweight$110.00 ➝ $125.00Low
10/7/2020Wells Fargo & CompanyBoost Price TargetOverweight$120.00 ➝ $122.00Low
9/11/2020Wolfe ResearchInitiated CoverageOutperform$124.00Low
9/2/2020The Goldman Sachs GroupSet Price TargetSell$94.00Low
8/31/2020Credit Suisse GroupBoost Price TargetOutperform$109.00 ➝ $136.00Low
8/28/2020CitigroupBoost Price TargetBuy$110.00 ➝ $130.00High
8/27/2020BTIG ResearchReiterated RatingHoldHigh
8/27/2020The Goldman Sachs GroupSet Price TargetSell$94.00Medium
8/27/2020Wells Fargo & CompanyBoost Price Target$107.00 ➝ $115.00Medium
8/27/2020Stifel NicolausBoost Price TargetBuy$108.00 ➝ $115.00Low
8/27/2020Morgan StanleyBoost Price TargetOverweight$106.00 ➝ $112.00Medium
7/23/2020ArgusBoost Price Target$110.00 ➝ $125.00Low
7/20/2020Bank of AmericaBoost Price TargetBuy$95.00 ➝ $110.00Medium
7/17/2020SVB LeerinkBoost Price TargetMarket Perform$97.00 ➝ $110.00High
7/17/2020Morgan StanleyBoost Price TargetOverweight$100.00 ➝ $106.00High
7/17/2020Credit Suisse GroupBoost Price TargetOutperform$106.00 ➝ $109.00High
7/17/2020CitigroupBoost Price TargetBuy$109.00 ➝ $110.00Medium
7/9/2020Wells Fargo & CompanyReiterated RatingBuy$107.00Low
6/25/2020Morgan StanleyLower Price TargetOverweight$108.00 ➝ $100.00High
5/31/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$84.00Medium
5/22/2020Credit Suisse GroupReiterated RatingBuy$106.00Low
4/20/2020BarclaysBoost Price TargetOverweight$92.00 ➝ $100.00Medium
4/17/2020UBS GroupBoost Price TargetBuy$105.00 ➝ $109.00Low
4/17/2020JPMorgan Chase & Co.Boost Price TargetOverweight$88.00 ➝ $98.00Low
4/17/2020Stifel NicolausBoost Price Target$85.00 ➝ $108.00Low
4/17/2020Credit Suisse GroupBoost Price TargetOutperform$95.00 ➝ $106.00Medium
4/17/2020Raymond JamesBoost Price TargetOverweight ➝ Outperform$92.00 ➝ $102.00Low
4/17/2020CitigroupBoost Price TargetBuy$87.00 ➝ $109.00Medium
4/17/2020Wells Fargo & CompanyBoost Price TargetOverweight$95.00 ➝ $107.00Medium
4/16/2020BTIG ResearchReiterated RatingHoldLow
4/16/2020CfraBoost Price TargetBuy$99.00 ➝ $101.00Low
4/9/2020Wells Fargo & CompanyBoost Price TargetOverweight$92.00 ➝ $95.00Medium
4/9/2020Raymond JamesLower Price TargetOutperform$99.00 ➝ $92.00Medium
4/8/2020Wells Fargo & CompanyReiterated RatingBuyMedium
4/8/2020SVB LeerinkLower Price TargetMarket Perform$102.00 ➝ $93.00High
4/3/2020JPMorgan Chase & Co.Lower Price TargetOverweight$101.00 ➝ $88.00Low
3/30/2020Wells Fargo & CompanyReiterated RatingBuyMedium
3/27/2020CitigroupLower Price TargetBuy$96.00 ➝ $87.00Medium
3/27/2020Morgan StanleyLower Price TargetOverweight$101.00 ➝ $96.00Medium
3/6/2020Credit Suisse GroupLower Price TargetOutperform$104.00 ➝ $94.00High
3/4/2020CitigroupInitiated CoverageBuy$96.00Medium
2/12/2020The Goldman Sachs GroupInitiated CoverageNeutral$96.00Low
2/6/2020BTIG ResearchReiterated RatingHoldLow
1/23/2020JPMorgan Chase & Co.Lower Price Target$96.00 ➝ $101.00Low
1/23/2020UBS GroupBoost Price TargetBuy$99.00 ➝ $105.00Low
1/23/2020Wells Fargo & CompanyBoost Price TargetOverweight$97.00 ➝ $103.00Medium
1/23/2020Raymond JamesBoost Price TargetOutperform$90.00 ➝ $99.00Medium
1/23/2020Stifel NicolausBoost Price TargetBuy$95.00 ➝ $104.00Medium
1/2/2020CitigroupDowngradeNeutral ➝ SellHigh
1/2/2020Evercore ISIDowngradeOutperform ➝ In-LineHigh
1/2/2020GuggenheimDowngradeBuy ➝ NeutralMedium
12/17/2019Morgan StanleyBoost Price TargetOverweight$93.00 ➝ $101.00Medium
10/17/2019William BlairReiterated RatingUnderperformLow
10/17/2019Credit Suisse GroupBoost Price TargetOutperform$95.00 ➝ $98.00Low
10/14/2019Raymond JamesLower Price TargetOutperform$93.00 ➝ $90.00Low
7/18/2019Jefferies Financial GroupBoost Price TargetBuy$80.00 ➝ $98.00Medium
7/18/2019CowenBoost Price TargetOutperform$86.00 ➝ $95.00High
7/18/2019Raymond JamesBoost Price TargetOutperform$87.00 ➝ $93.00Medium
7/18/2019BMO Capital MarketsBoost Price TargetOutperform$87.00 ➝ $94.00Medium
7/16/2019Morgan StanleyBoost Price TargetOverweight$85.00 ➝ $93.00Low
6/13/2019Bank of AmericaReiterated RatingBuy$81.00Low
6/13/2019Wells Fargo & CompanyBoost Price TargetOutperform$89.00 ➝ $91.00Low
4/18/2019William BlairReiterated RatingOutperformN/A
4/15/2019Royal Bank of CanadaBoost Price TargetBuy$82.00Low
3/14/2019Wells Fargo & CompanyReiterated RatingBuyHigh
3/8/2019BarclaysSet Price TargetBuy$84.00Low
2/7/2019Bank of AmericaReiterated RatingBuy ➝ Buy$73.00 ➝ $81.00Low
1/25/2019ArgusBoost Price TargetBuy ➝ In-Line$90.00Low
1/24/2019BTIG ResearchReiterated RatingHoldMedium
1/2/2019GabelliReiterated RatingBuyLow
1/2/2019Morgan StanleyBoost Price TargetOverweight ➝ Overweight$82.00 ➝ $85.00Low
1/2/2019CitigroupDowngradeNeutral ➝ Sell$72.00 ➝ $68.00High
12/17/2018Credit Suisse GroupInitiated CoverageOutperform$82.00Low
12/9/2018The Goldman Sachs GroupUpgradeNeutral ➝ Buy$74.10Low
12/4/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$80.00 ➝ $82.00High
11/30/2018The Goldman Sachs GroupUpgradeNeutral ➝ Buy$78.00 ➝ $81.00Low
11/27/2018UBS GroupInitiated CoverageBuy$83.00High
10/18/2018Jefferies Financial GroupReiterated RatingIn-Line ➝ Buy$80.00High
10/18/2018Raymond JamesBoost Price TargetOutperform ➝ Outperform$77.00 ➝ $79.00High
10/18/2018BTIG ResearchReiterated RatingHoldHigh
10/15/2018BarclaysInitiated CoverageOverweight ➝ Overweight$80.00High
10/11/2018Morgan StanleyBoost Price TargetOverweight$70.00 ➝ $80.00Medium
10/11/2018Royal Bank of CanadaBoost Price TargetOutperform$77.00Low
10/8/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$77.00 ➝ $81.00Low
10/5/2018CowenBoost Price TargetOutperform ➝ Average$72.00 ➝ $86.00Low
9/24/2018Raymond JamesBoost Price TargetOutperform ➝ Outperform$72.00 ➝ $77.00Medium
9/24/2018Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$77.00 ➝ $80.00Medium
7/19/2018Royal Bank of CanadaReiterated RatingBuy$70.00Low
7/19/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$71.00 ➝ $72.00Medium
6/27/2018Sanford C. BernsteinInitiated CoverageOutperform$73.00Medium
4/24/2018CitigroupLower Price TargetNeutral ➝ Neutral$66.00 ➝ $65.00Low
4/22/2018BTIG ResearchReiterated RatingHoldLow
1/30/2018ArgusBoost Price TargetBuy$66.00 ➝ $80.00Low
1/30/2018CitigroupBoost Price TargetNeutral ➝ Neutral$59.00 ➝ $64.00Low
1/25/2018BarclaysBoost Price TargetOverweight ➝ Overweight$66.00 ➝ $70.00Low
1/25/2018GuggenheimReiterated RatingBuy$72.00Low
1/25/2018Royal Bank of CanadaReiterated RatingBuy$67.00Low
1/25/2018SVB LeerinkReiterated RatingMarket Perform$60.00 ➝ $68.00Low
1/25/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$65.00 ➝ $69.00High
1/25/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$67.00 ➝ $70.00High
1/25/2018Wells Fargo & CompanyBoost Price TargetOutperform$66.00 ➝ $70.00Medium
1/25/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$65.00 ➝ $70.00Medium
1/25/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$63.00 ➝ $71.00Medium
1/25/2018William BlairUpgradeMarket Perform ➝ OutperformMedium
1/24/2018Bank of AmericaBoost Price Target$60.00 ➝ $70.00High
1/22/2018BTIG ResearchDowngradeBuy ➝ NeutralMedium
1/19/2018SVB LeerinkReiterated RatingMarket PerformLow
1/9/2018Royal Bank of CanadaReiterated RatingBuy$65.00Low
1/8/2018BarclaysReiterated RatingBuy$66.00Low
1/3/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$64.00Low
1/2/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$60.00 ➝ $60.00Low
1/2/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$67.00Low
12/12/2017BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$58.00 ➝ $65.00Medium
10/19/2017BarclaysReiterated RatingOverweightN/A
10/19/2017CitigroupReiterated RatingNeutralN/A
10/19/2017BMO Capital MarketsReiterated RatingMarket PerformN/A
10/19/2017CowenSet Price TargetBuy$55.00 ➝ $68.00N/A
10/19/2017Stifel NicolausBoost Price TargetBuy ➝ Buy$58.00 ➝ $63.00N/A
10/19/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$55.00 ➝ $60.00N/A
10/19/2017Jefferies Financial GroupReiterated RatingBuy$65.00N/A
10/6/2017JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$60.00N/A
10/4/2017Bank of AmericaReiterated RatingBuy$56.00 ➝ $60.00N/A
10/3/2017Royal Bank of CanadaReiterated RatingBuy$55.00Low
10/2/2017BMO Capital MarketsReiterated RatingHold$53.00Low
9/28/2017BarclaysBoost Price TargetOverweight$57.00 ➝ $60.00Low
9/28/2017Wells Fargo & CompanyBoost Price TargetOutperform$57.00 ➝ $64.00Low
9/24/2017CowenReiterated RatingBuyLow
9/1/2017BMO Capital MarketsReiterated RatingHold$53.00N/A
8/17/2017CitigroupInitiated CoverageNeutral ➝ Neutral$53.00Medium
8/17/2017CowenReiterated RatingBuy$55.00Medium
8/3/2017Jefferies Financial GroupReiterated RatingBuy$58.00Low
7/22/2017BarclaysReiterated RatingOverweight$52.00 ➝ $57.00Low
7/21/2017Stifel NicolausReiterated RatingBuy$58.00Low
7/14/2017CowenReiterated RatingOutperform$48.00 ➝ $55.00Low
7/11/2017BMO Capital MarketsReiterated RatingHold$48.00Low
7/10/2017Morgan StanleyReiterated RatingEqual WeightLow
6/30/2017Wells Fargo & CompanyReiterated RatingOutperform$47.50 ➝ $54.00Low
6/29/2017Jefferies Financial GroupReiterated RatingBuy$58.00Low
6/29/2017GuggenheimInitiated CoverageBuy$58.00Low
6/21/2017BTIG ResearchReiterated RatingBuy$56.00Low
6/16/2017Jefferies Financial GroupReiterated RatingBuy$55.00Low
5/31/2017Stifel NicolausBoost Price TargetBuy$49.00 ➝ $51.00Medium
5/16/2017The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$45.00Low
5/15/2017Royal Bank of CanadaReiterated RatingBuyLow
5/12/2017Jefferies Financial GroupReiterated RatingBuy$50.00 ➝ $51.00Low
4/22/2017CowenReiterated RatingOutperform$48.00Medium
4/20/2017BarclaysBoost Price TargetOverweight ➝ Overweight$50.00 ➝ $52.00Low
4/19/2017Morgan StanleyReiterated RatingEqual Weight$42.00Low
4/18/2017UBS GroupReiterated RatingNeutral$41.00N/A
4/18/2017Jefferies Financial GroupLower Price TargetBuy$52.00 ➝ $50.00Medium
4/18/2017Stifel NicolausReiterated RatingBuy$49.00Medium
4/13/2017CowenReiterated RatingBuy$48.00Low
3/14/2017BMO Capital MarketsDowngradeOutperform ➝ Market Perform$48.00Medium
3/11/2017Jefferies Financial GroupReiterated RatingBuy$51.00 ➝ $52.00N/A
3/1/2017Royal Bank of CanadaBoost Price TargetOutperform$46.00 ➝ $50.00N/A
2/17/2017Jefferies Financial GroupReiterated RatingBuy$51.00N/A
1/26/2017Royal Bank of CanadaLower Price TargetOutperform$48.00 ➝ $46.00N/A
1/20/2017Jefferies Financial GroupBoost Price TargetBuy$47.00 ➝ $48.00N/A
1/13/2017Jefferies Financial GroupBoost Price TargetBuy$46.00 ➝ $47.00N/A
12/20/2016Jefferies Financial GroupReiterated RatingBuy$46.00N/A
9/19/2016Bank of AmericaReiterated RatingBuyN/A
9/19/2016Royal Bank of CanadaReiterated RatingOutperform$48.00N/A
9/13/2016Jefferies Financial GroupLower Price TargetBuy$52.00 ➝ $48.00N/A
8/12/2016Bank of AmericaReiterated RatingBuy$50.00N/A
8/10/2016BTIG ResearchReiterated RatingBuy$45.00N/A
8/9/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
8/4/2016Jefferies Financial GroupBoost Price TargetBuy$49.00 ➝ $52.00N/A
7/28/2016ArgusReiterated RatingBuy$55.00N/A
7/21/2016BarclaysBoost Price TargetOverweight$48.00 ➝ $50.00N/A
7/21/2016UBS GroupReiterated RatingHold$45.00N/A
7/14/2016Jefferies Financial GroupBoost Price TargetBuy$45.00 ➝ $49.00N/A
7/12/2016BarclaysReiterated RatingOverweight$48.00N/A
6/21/2016Edward JonesUpgradeHold ➝ BuyN/A
6/18/2016BarclaysReiterated RatingBuy$48.00N/A
(Data available from 6/18/2016 forward)
Abbott Laboratories logo
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Read More

Today's Range

Now: $110.33
Low: $110.00
High: $111.35

50 Day Range

MA: $116.70
Low: $105.79
High: $124.53

52 Week Range

Now: $110.33
Low: $86.16
High: $128.54

Volume

8,746,533 shs

Average Volume

5,746,382 shs

Market Capitalization

$196.04 billion

P/E Ratio

34.59

Dividend Yield

1.61%

Beta

0.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Abbott Laboratories?

The following sell-side analysts have issued reports on Abbott Laboratories in the last year: Argus, Atlantic Securities, Bank of America Co., Barclays PLC, BTIG Research, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Credit Suisse Group AG, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Raymond James, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., Wells Fargo & Company, William Blair, Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for ABT.

What is the current price target for Abbott Laboratories?

18 Wall Street analysts have set twelve-month price targets for Abbott Laboratories in the last year. Their average twelve-month price target is $121.56, suggesting a possible upside of 10.0%. Cowen Inc has the highest price target set, predicting ABT will reach $140.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $94.00 for Abbott Laboratories in the next year.
View the latest price targets for ABT.

What is the current consensus analyst rating for Abbott Laboratories?

Abbott Laboratories currently has 1 sell rating, 2 hold ratings and 15 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ABT will outperform the market and that investors should add to their positions of Abbott Laboratories.
View the latest ratings for ABT.

What other companies compete with Abbott Laboratories?

How do I contact Abbott Laboratories' investor relations team?

Abbott Laboratories' physical mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker's listed phone number is 224-667-6100. The official website for Abbott Laboratories is www.abbott.com.